

29 **Abstract**

30 **Objectives**

31 To examine the characteristics and trends in the industry payments to emergency
32 physicians since the inception of the Open Payments Database in 2013 and the COVID-
33 19 pandemic in 2020.

34

35 **Methods**

36 Using the Open Payments Database between August 2013 and December 2021, this
37 population-based cohort study examined all research and general payments made by the
38 healthcare industry to emergency physicians registered in the National Plan and
39 Provider Enumeration System in the United States. We performed descriptive analyses
40 on payment data and generalized estimating equations for payment trends.

41

42 **Results**

43 Among 50,483 active emergency physicians, 28,678 (56.8%) accepted a total of
44 \$457,640,796.73 payments from the healthcare industry between 2013 and 2021. 56.6%
45 and 1.3% of all emergency physicians received general and research payments,
46 respectively. 20.8% (\$94.98 millions) of overall industry payments were general
47 payments. Median general and research payments per-physician (interquartile range)
48 were \$133.21 (\$44.78–\$355.77) and \$62,842.97 (\$10,320.00–\$273,285.28),
49 respectively. Top 1% of emergency physicians received 86.2% of overall general
50 payments, respectively. The number of physicians receiving general payments decreased
51 by 2.9% (95% CI: -3.2 to -2.5, $p < 0.001$) annually between 2014 and 2019 and 47.8%
52 (95% CI: -49.8 to -45.6, $p < 0.001$) in 2020. Although there were no significant changes
53 in research payments before COVID-19 pandemic, the research payments significantly
54 increased by 69.4% (95% CI: 28.9–122.7, $p < 0.001$) in 2021 than those in 2020.

55

56 **Conclusions**

57 Majority of emergency physicians accepted general payments from the healthcare
58 industry, but the number of emergency physician accepting the general payments
59 significantly decreased since the inception of Open Payments Database.

60

61 **Key words**

62 Open Payments Database; conflict of interest; industry payments; ethics; health policy;
63 emergency medicine; emergency physician; United States

64

65 **Introduction**

66 Financial relationships between physicians and the healthcare industry are widespread
67 for research and non-research purposes in the United States (US).[1,2] In response to
68 increased public demand for greater transparency and revelation of their negative
69 impact on physicians' clinical practice and research, the Physician Payments Sunshine
70 Act was enacted in 2010. It legally mandates all pharmaceutical and medical devices
71 manufacturers to disclose their payments to physicians on a federal transparency
72 database, the Open Payments Database since 2013.[1,3,4]

73
74 Open Payments Database contains comprehensive physician-industry financial
75 relationships in the US, including emergency physicians. Two previous studies using the
76 Open Payments reported physician-industry financial relationships in the field of
77 emergency medicine. Fleischman et al. first reported about one third of emergency
78 physicians received general payments in 2014.[5] Later, Niforatos et al. documented
79 that more than one third of emergency physician still received general payments from
80 the healthcare industry in 2017.[6]

81
82 Although previous studies on emergency physicians in the US exists, little is known
83 about the longitudinal trends in the industry payments to emergency physicians since
84 the inception of the Open Payments Database in 2013. Additionally, the sudden onset of
85 COVID-19 pandemic significantly impacted physician activities and industry marketing
86 strategies in the US, [7,8] while there was no document concerning the emergency
87 physician-industry relationships during the COVID-19 pandemic. This study conducted
88 the first longitudinal analysis with large sample size spotlighting the whole picture of
89 the magnitude, prevalence, and trends in the physician-industry financial relationships
90 since the inception of the Open Payments Database and the COVID-19 pandemic in the
91 US in the field of emergency medicine.

92

93

94 **Methods**

95 *Study design and setting and Selection of Participants*

96 This cross-sectional analysis evaluated the magnitude, prevalence, and trend in both
97 general and research payments to emergency physicians since the inception of the Open
98 Payments database in 2013. This study defined emergency physician as a physician
99 whose primary specialty was categorized as emergency medicine and entailed
100 subspecialties in the National Plan and Provider Enumeration System (NPPES) database.

101 All emergency physicians who registered to the NPPES before August 1, 2013, were
102 included in this study. As this is longitudinal analysis aiming to examine the trends in
103 industry payments, emergency physicians who newly activated or deactivated after
104 August 1, 2013, were excluded from the study sample.

105

106 ***The Open Payments Database and data collection***

107 The payments and relevant data were collected in the following steps. First, all profile
108 data of emergency physicians were extracted from the NPPES database. Second, the
109 extracted NPPES dataset were matched with the Open Payments physician profile
110 database using the National Provider Identifier number. Third, all general payments
111 made to the emergency physicians between August 2013 and December 2021 were
112 extracted from the Open Payments payment database using the covered recipient
113 numbers. Finally, for the research payments, all research payments of which the
114 principal investigator's NPPES primary specialty was emergency medicine were
115 collected. This method includes indirectly paid research payments via third parties (e.g.
116 teaching hospitals and universities), preventing underestimation of the magnitude and
117 prevalence of research payments, as shown by previous studies.[9,10]

118

119 ***Outcome and statistical analyses***

120 This study conducted descriptive analysis on the extracted payments data on individual
121 physician level. Per-physician payments were calculated only among physicians
122 receiving payments each year and overall, as performed in other previous
123 studies.[1,3,11-13] Per-physician payments were calculated based on total amounts of
124 payments divided by the number of principal investigators in a research payment.
125 To examine the concentration of general and research payments per physician, the share
126 of payments by specific proportions of physicians and the Gini index were calculated.
127 The Gini index ranges from 0 indicating complete equality to 1 indicating complete
128 inequality.[12,13]
129 Additionally, the trends in general and research payments were evaluated by the
130 population-averaged generalized estimating equations (GEE) model with panel-data of
131 annual payments per physician clustering each physician level, as noted
132 previously.[7,8,13,14] To take in account in the influence of the COVID-19 pandemic
133 since 2020, interrupted time series (ITS) analysis were employed. The ITS analysis with
134 robust negative binomial regression GEE model for trend in payments per physician and
135 ITS analysis with modified robust log-linked regression GEE model with Poisson
136 distribution for trend in the number of physicians receiving payments between 2014 and

137 2021 were applied, as the payments were highly skewed.[13,14] Payment data in 2013
138 was excluded from the trend analysis, as the payment data in 2013 was partially
139 disclosed between August and December 2013. The research payment data were
140 rounded down as a unit of \$10,000 to stabilize the ITS GEE model. The study also
141 conducted ITS analysis excluding the payments for acquisitions, debt forgiveness, long-
142 term medical supply or device loans, ownership interests, and royalties and licenses,
143 because there were substantial amounts of general payments for royalties and license in
144 several years or these payment categories were newly-added in 2021. All data extraction
145 and data analyses were performed with Python 3.9.12 (Python Software Foundation,
146 Beaverton, OR, US), Microsoft Excel, version 17.0 (Microsoft Corp., Redmond, WA,
147 US), and Stata version 15 (StataCorp, College Station, TX, US).

148

149 ***Ethical clearance***

150 No institutional board review and approval were required for this study as all data used
151 met the definition of freely available public data.

152

153

154 **Results**

155 ***Overview of industry payments to emergency physicians***

156 There were 50,483 active emergency physicians as of August 1, 2013, in the NPPES
157 database. Among 50,483 active emergency physicians, 28,678 or 56.8% of all
158 emergency physicians received a total of 420,967 summing \$457,640,796 from 1210
159 different companies between 2013 and 2021.

160

161 ***General payments***

162 As of general payments, 28,590 emergency physicians (56.6%) received 321,428
163 general payments totaling \$94,977,251 (20.8% of overall industry payments) from 1145
164 different companies over the nine years. 16 (0.005%) general payments were under
165 dispute and 15 (93.8%) were unchanged. Median payment was \$17.32 (interquartile
166 [IQR]: \$13–\$73), while average payment was \$299 (standard deviation [SD]: \$22,103).
167 Median total payments per physician were \$133 (IQR: \$45–\$356) and average
168 payments were \$3,322 (SD: \$91,063). (Table 1) Median annual total general payments
169 ranged from \$31 (IQR: \$16–\$103) in 2020 to \$54 (IQR: \$19–\$131) in 2014. Gini index
170 for the total general payments per physician was 0.975, suggesting the only the very
171 small number of emergency physicians received substantial amounts of general
172 payments. Only top 1%, 5%, 10%, and 25% of all emergency physicians received

173 86.2%, 94.4%, 96.5%, and 98.9%, respectively. Gini index was 0.975 for per-physician
174 general payments, showing that only the very small number of emergency physicians
175 received substantial amounts of general payments.

176

177 Table 2 describes the general payments by payment categories. Of 15 payment
178 categories, payments for speaking fees other than continuous medical education (CME)
179 purposes occupied 38.5% (\$36,522,818) in monetary values, while only 841 (1.7%)
180 emergency physicians received 9,101 (2.8%) payments. Meanwhile, only 0.2% (109)
181 emergency physicians received 703 (0.2%) payments for CME speaking purposes
182 totaling \$1,521,937 (1.6%). Payments for food and beverage was the largest number of
183 emergency physicians receiving payments and number of payments, with 27,966
184 (55.4% of all emergency physicians) and 274,678 (85.5% of overall). The payments
185 with the second and third largest number of physicians receiving payments were
186 education and travel payments with 2,964 (5.9%) and 1,543 (3.1%), respectively.

187

188 ***Research payments***

189 Only 663 equivalent to 1.3% of all emergency physicians received 99,539 research
190 payments summed \$362,663,547 (79.2% of overall industry payments) from 272
191 companies between 2013 and 2021. No research payment was disputed. Per-physician
192 research payments were \$62,843 (IQR: \$10,320–\$273,285) in median and \$547,004
193 (SD: \$1,884,010) in average. Median annual total general payments ranged from
194 \$19,541 (IQR: \$3,676–\$95,671) in 2014 to \$44,943 (IQR: \$11,453–\$200,961) in 2021.
195 Gini index was 0.998 for per-physician nine-year combined research payments. Among
196 663 emergency physicians receiving research payments, 575 (86.7%) received \$1,121
197 (IQR: \$160–\$7,491) in median total general payments, while emergency physicians
198 without research payments received \$131 (IQR: \$44–\$342) in median.

199 Of 99,539 research payments, only 786 research payments totaling \$4.62 million, equal
200 to 0.8% in the number of payments and 1.3% in monetary values of overall research
201 payments, were made for preclinical research. Additionally, there were 5,579 research
202 payments totaling \$56,925,292 (15.7% of all research payments) related to 296 different
203 registered clinical trials. Emergency physician principal investigators of a randomized,
204 placebo-controlled trial assessing efficacy of bamlanivimab and etesevimab in mild to
205 moderate COVID-19 patients (ClinicalTrials.gov Identifier: NCT04427501)[15]
206 received the largest total research payments of \$5,449,62, followed by a clinical trial
207 assessing safety and efficacy of SARS-CoV-2 monoclonal antibodies (ClinicalTrials.gov
208 Identifier: NCT04425629)[16] with \$4,638,617 and a clinical trial assessing the

209 efficacy of alone or in combination of SARS-CoV-2 monoclonal antibodies
210 (ClinicalTrials.gov Identifier: NCT04634409)[17] with \$4,021,590.

211

212 ***Summary and Trends in annual general and research payments***

213 12.9% to 26.0% of emergency physicians received one or more general payments each
214 year. (Table 1) The number of emergency physicians accepting general payments was
215 the highest (13,126; 26.0%) in 2015 and then constantly decreased to 9,935 (19.7%) in
216 2019. Similarly, the median annual total payments per physician decreased from \$54 in
217 2014 to \$47 in 2018, but increased in 2019. The number of emergency physicians
218 accepting general payments significantly decreased each year between 2014 and 2019,
219 with the relative annual percentage change (RAPC) of -2.9% (95% CI: -3.2 to -2.5,
220 $p<0.001$), while there was no significant change in the per-physician total general
221 payments. (Table 4)

222 When the COVID-19 pandemic occurred in the US in 2020, the total annual amounts,
223 number of general payments, and the number of emergency physicians accepting
224 payments substantially decreased between 2019 and 2020. The general payments per
225 physician and the number of physicians accepting general payments decreased by
226 45.4% (95% CI: -57.7 to -29.6, $p<0.001$) and 47.8% (95% CI: -49.8 to -45.6, $p<0.001$)
227 in 2020 compared to those between 2014 and 2019. (Table 4) During the COVID-19
228 pandemic period between 2020 and 2021, the per-physician general payments and the
229 number of emergency physicians accepting general payments increased by RAPCs of
230 25.7% (95% CI: 5.9–49.2, $p=0.009$) and 21.7% (95% CI: 19.8–24.8, $p<0.001$),
231 respectively.

232

233 Annual total research payments ranged from \$29,602,868 in 2018 to \$56,888,938 in
234 2021. (Table 3) Meanwhile, the number of emergency physicians receiving research
235 payments was the lowest at 188 (0.4% of all emergency physicians) in 2021 and the
236 highest at 304 (0.6%) in 2016. There were no clinically meaningful changes in research
237 payments between 2014 and 2019. (Table 4) Also, there were no changes in research
238 payments before and during the COVID-19 period, but the per-physician research
239 payments significantly increased by 69.4% (95% CI: 28.9–122.7, $p<0.001$) in 2021
240 compared to those in 2020. (Table 4)

241

242 **Discussion**

243 To the best of my knowledge to date, this study is the first longitudinal analysis of both
244 non-research and research financial relationships between emergency physicians and the

245 healthcare industry using the Open Payments Database since the inception of the
246 database in the US. The study brought several novel and important insights into the
247 emergency physicians-industry financial relationships. This study illustrated that 56.8%
248 of all active emergency physicians received 420,967 industry payments totaling more
249 than \$457 million from the healthcare industry in the US between 2013 and 2021. About
250 one fifth of overall industry payments were made to emergency physicians as general
251 payments, more than 70% of which were for speaking compensations for non-CME
252 events and consulting fees. The very small number of emergency physicians received
253 considerable amounts of general payments. While the payment amounts did not change,
254 the number of emergency physicians accepting general payments significantly
255 decreased since the inception of the Open Payments program in the United States.
256 Additionally, only 1.3% of all emergency physician received research payments from
257 the healthcare industry over the nine years period. There had been no change in research
258 payments since the inception of the Open Payments Database, but the COVID-19
259 pandemic brought the substantial amounts of research payments to the very small
260 number of emergency physicians.

261
262 There were differences in results between this analysis and previous studies. The
263 findings showed that lower proportion of emergency physicians receiving payments but
264 the per-physician payments was higher than those in previous studies.[5,6] Two
265 previous studies reported that 30.1% to 35.4% of all emergency physicians received \$18
266 to \$44 in median total general payments per physician.[5,6] However, the study found
267 that 12.9% to 26.0% of emergency physicians accepted \$31–\$54 in median annual
268 general payments. This difference in the proportion of emergency physician with
269 payments could be due to the difference in the data sampling methods between the
270 previous studies and this study. The previous studies estimated the proportion of
271 emergency physicians receiving payments from the Association of American Medical
272 College Physician Specialty Data Report, while this study included all emergency
273 physicians registered in the NPPES database. As Ahlawat et al. suggested, the NPPES
274 database might have included larger number of physicians and might underestimate the
275 proportion of physicians receiving payments. Also, as for the difference in payment
276 amounts, the Open Payments Database includes many errors in specialty categorization
277 in payment database. Even when payments were made to a same physician in one year,
278 the several different specialties were assigned to the physician receiving payments in the
279 payment database, as previously observed in rheumatology, allergology, and infectious
280 diseases.[7,8,14] This difference in physician specialty could be caused by payment data

281 being submitted by each company making a payment. Rigorous data collection process
282 of this study could extract all payments made to the emergency physicians using the
283 NPPES database and minimize the possibility of underestimation of per-physician
284 payments.

285

286 Through the rigorous methodology, this study elucidated that the emergency physicians
287 were the specialists with the lowest general payments (\$31–\$54 in median annual per-
288 physician payments) made by the healthcare industry over the nine years. For other
289 specialties, the median annual general payments per physician were \$94 in
290 pediatricians,[2] \$140 in obstetrics and gynecology,[18] \$197–\$220 in infectious
291 diseases,[14] \$395–\$597 in allergology and clinical immunology,[7] \$407 in
292 neurology,[19] \$579–\$616 in cardiology,[12] \$648–\$795 in oncology,[20] \$500–\$812
293 in rheumatology.[8] This finding was consistent with previous studies.[2,5,6] As
294 Fleischman et al. pointed out, the healthcare industry has less incentive to make general
295 payments to emergency physicians, as emergency physicians often provide short-term
296 prescriptions and less expensive pharmacotherapy compared to other specialists.[5]

297

298 Notably, there were steadily decreasing trends in the number of emergency physician
299 accepting general payments before the COVID-19 pandemic. In addition, the COVID-
300 19 pandemic has significantly restricted the financial relationships between emergency
301 physicians and the healthcare industry. Although the Open Payments Database was
302 created to improve the transparency in the physician-industry financial relationships, it
303 was also expected to decrease the influence of the healthcare industry on physician
304 practices and patient care through public scrutiny and pressure on that
305 relationship.[4,8,21] While the industry payments had been decreasing since the
306 inception of the Open Payments Database in entire, but the increasing trends were
307 recorded in several specialties such as oncology,[22] allergology,[7] rheumatology,[8]
308 and infectious diseases.[14] Considering that even a small food and beverage payment
309 significantly influence physician prescribing patterns[23-25] and substantial amounts of
310 these payments and gifts sometimes made for promotions of drugs with less safety and
311 lower efficacy with invalid evidence,[23,24,26] all physicians including emergency
312 physicians should decline accepting the industry payments and gifts made for marketing
313 purposes, even though physicians believe those financial interactions are beneficial and
314 inconceivable to influence their clinical practice.[27]

315

316 Although the research payments included not only payments directly made to the

317 emergency physicians but also costs for drugs, medical devices, and experimental
318 equipment, inclusion of all research payments of which principal investigators were
319 emergency physicians elucidated that the healthcare industry made nearly 80% of their
320 expense to emergency physicians for research purposes. Additionally, only 1.3% of
321 emergency physicians received those substantial research payments. Considering that,
322 in previous studies conducted using the same methodology as this study, the percentage
323 of physicians receiving research payments was approximately 7% in urology[28] and
324 11% in neurosurgery,[29] the research payments disproportionately concentrated on a
325 much smaller number of physicians in the emergency medicine field. While there was
326 increasing trend in research payments after 2020, these increased research payments
327 were made to trials developing treatments for COVID-19 and the number of emergency
328 physicians did not substantially change over the nine years. Therefore, the research
329 payments from the healthcare industry could have temporarily increased and will
330 decrease after the pandemic.

331
332 This study has a number of limitations. First, despite the physicians can review and
333 dispute the payment data listed in the Open Payments Database, possible inaccuracy in
334 the Open Payments Database could not be excluded as indicated by previous
335 studies.[11,19] Second, the NPPES physician specialty was determined by self-
336 declaration of each physician. As the methodological difference of physician specialty
337 categorization between the NPPES database, the American Medical Association
338 Physician Masterfile, and the Association of American Medical College Physician
339 Specialty Data Report which is created from American Medical Association Physician
340 Masterfile database, the number of emergency physicians might be overestimated, as
341 pointed out by Ahlawat et al.[19] Third, there would be unmeasured confounding
342 factors influencing the amounts of and trends in industry payments such as physician
343 age, position in their affiliation, career status, and race/ethnicity, and approval timing of
344 novel drugs in emergency medicine of which information was not available through the
345 NPPES database and the Open Payments Database.

346

347 ***Conclusion***

348 Majority of active emergency physicians received the general payments from the
349 healthcare industry in the United States since the inception of the Open Payments
350 Database. Only a small number of emergency physicians received considerable amounts
351 of research and general payments. The general payments to the emergency physicians
352 have been decreasing since the inception of the Open Payments Database in 2013, while

353 the research payments were increasing due to the development of COVID-19 treatments.

354

355

356 **References**

- 357 [1] Marshall DC, Jackson ME, Hattangadi-Gluth JA. Disclosure of Industry Payments to
358 Physicians: An Epidemiologic Analysis of Early Data From the Open Payments Program. *Mayo*
359 *Clin Proc.* 2016;91(1):84-96. <https://doi.org/10.1016/j.mayocp.2015.10.016>.
- 360 [2] Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD, Hattangadi-Gluth JA.
361 Types and Distribution of Payments From Industry to Physicians in 2015. *JAMA.*
362 2017;317(17):1774-84. <https://doi.org/10.1001/jama.2017.3091>.
- 363 [3] Oberlin DT, Gonzalez CM. Industry Ties in Medicine: Insight from the Open
364 Payments Program. *Mayo Clinic Proceedings.* 2016;91(5):685-6.
365 <https://doi.org/10.1016/j.mayocp.2016.02.003>.
- 366 [4] Pham-Kanter G. Act II of the Sunshine Act. *PLoS Med.* 2014;11(11):e1001754.
367 <https://doi.org/10.1371/journal.pmed.1001754>.
- 368 [5] Fleischman W, Ross JS, Melnick ER, Newman DH, Venkatesh AK. Financial Ties
369 Between Emergency Physicians and Industry: Insights From Open Payments Data. *Annals of*
370 *Emergency Medicine.* 2016;68(2):153-8.e4.
371 <https://doi.org/10.1016/j.annemergmed.2016.01.014>.
- 372 [6] Niforatos JD, Boas S, Hertz S, Ozgur A, Raja AS. Analysis of current financial
373 relationships between emergency physicians and industry. *The American Journal of Emergency*
374 *Medicine.* 2019;37(4):722-5. <https://doi.org/https://doi.org/10.1016/j.ajem.2018.12.039>.
- 375 [7] Murayama A, Kamamoto S, Saito H, Tanimoto T, Ozaki A. Industry payments to
376 allergists and clinical immunologists in the United States during the coronavirus disease 2019
377 pandemic. *Ann Allergy Asthma Immunol.* 2022<https://doi.org/10.1016/j.anai.2022.08.006>.
- 378 [8] Murayama A, Kamamoto S, Higuchi K, Shigeta H, Ozaki A. Trend in industry
379 payments to rheumatologists in the United States during the COVID-19 pandemic between
380 2013 and 2021. *The Journal of Rheumatology.* 2022;jrheum.220512.
381 <https://doi.org/10.3899/jrheum.220512>.
- 382 [9] Ying X, Rosenblatt R, Fortune BE. Trends in Industry Payments to Gastroenterologists
383 and Hepatologists in the United States from 2014 to 2020. *Gastroenterology.*
384 2022<https://doi.org/https://doi.org/10.1053/j.gastro.2022.06.029>.
- 385 [10] Murayama A, Kugo H, Saito Y, Saito H, Tanimoto T, Ozaki A. A Nine-year
386 Investigation of Healthcare Industry Payments to Pulmonologists in the United States. *Ann Am*
387 *Thorac Soc.* 2023<https://doi.org/10.1513/AnnalsATS.202209-827OC>.
- 388 [11] Feng H, Wu P, Leger M. Exploring the Industry-Dermatologist Financial Relationship:

- 389 Insight From the Open Payment Data. *JAMA Dermatol.* 2016;152(12):1307-13.
390 <https://doi.org/10.1001/jamadermatol.2016.3037>.
- 391 [12] Annapureddy A, Murugiah K, Minges KE, Chui PW, Desai N, Curtis JP. Industry
392 Payments to Cardiologists. *Circ Cardiovasc Qual Outcomes.* 2018;11(12):e005016.
393 <https://doi.org/10.1161/CIRCOUTCOMES.118.005016>.
- 394 [13] Kusumi E, Murayama A, Kamamoto S, Kawashima M, Yoshida M, Saito H, et al.
395 Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal
396 payments from pharmaceutical companies between 2016 and 2019. *Blood Cancer J.*
397 2022;12(4):54. <https://doi.org/10.1038/s41408-022-00656-y>.
- 398 [14] Murayama A, Nakano K, Kamamoto S, Sato M, Saito H, Tanimoto T, et al. Trend in
399 industry payments to infectious disease physicians in the United States: a seven-year analysis of
400 non-research payments from Open Payments Database between 2014 and 2020. *Clin Microbiol*
401 *Infect.* 2022<https://doi.org/10.1016/j.cmi.2022.07.023>.
- 402 [15] Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, et al. Effect of
403 Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients
404 With Mild to Moderate COVID-19: A Randomized Clinical Trial. *Jama.* 2021;325(7):632-44.
405 <https://doi.org/10.1001/jama.2021.0202>.
- 406 [16] Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGEN-
407 COV Antibody Combination and Outcomes in Outpatients with Covid-19. *N Engl J Med.*
408 2021;385(23):e81. <https://doi.org/10.1056/NEJMoa2108163>.
- 409 [17] Nathan R, Shawa I, De La Torre I, Pustizzi JM, Hastrup N, Patel DR, et al. A
410 Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody
411 Therapies for SARS-CoV-2. *Infect Dis Ther.* 2021;10(4):1933-47.
412 <https://doi.org/10.1007/s40121-021-00515-6>.
- 413 [18] Tierney NM, Saenz C, McHale M, Ward K, Plaxe S. Industry Payments to
414 Obstetrician–Gynecologists: An Analysis of 2014 Open Payments Data. *Obstetrics &*
415 *Gynecology.* 2016;127(2),
416 https://journals.lww.com/greenjournal/Fulltext/2016/02000/Industry_Payments_to_Obstetrician_Gynecologists_28.aspx.
- 417
418 [19] Ahlawat A, Narayanaswami P. Financial relationships between neurologists and
419 industry: The 2015 Open Payments database. *Neurology.* 2018;90(23):1063-70.
420 <https://doi.org/10.1212/WNL.0000000000005657>.
- 421 [20] Rahman MW, Trivedi NU, Bach PB, Mitchell AP. Increasing Financial Payments From
422 Industry to Medical Oncologists in the United States, 2014–2017. *Journal of the National*
423 *Comprehensive Cancer Network.* 2021:1-9. <https://doi.org/10.6004/jnccn.2021.7024>.
- 424 [21] Marshall DC, Tarras ES, Rosenzweig K, Korenstein D, Chimonas S. Trends in Industry

- 425 Payments to Physicians in the United States From 2014 to 2018. *JAMA*. 2020;324(17):1785-8.
426 <https://doi.org/10.1001/jama.2020.11413>.
- 427 [22] Tarras ES, Marshall DC, Rosenzweig K, Korenstein D, Chimonas S. Trends in Industry
428 Payments to Medical Oncologists in the United States Since the Inception of the Open
429 Payments Program, 2014 to 2019. *JAMA Oncol*. 2021;7(3):440-4.
430 <https://doi.org/10.1001/jamaoncol.2020.6591>.
- 431 [23] Mitchell AP, Trivedi NU, Gennarelli RL, Chimonas S, Tabatabai SM, Goldberg J, et al.
432 Are Financial Payments From the Pharmaceutical Industry Associated With Physician
433 Prescribing? : A Systematic Review. *Ann Intern Med*. 2021;174(3):353-61.
434 <https://doi.org/10.7326/M20-5665>.
- 435 [24] Hartung DM, Johnston K, Cohen DM, Nguyen T, Deodhar A, Bourdette DN. Industry
436 Payments to Physician Specialists Who Prescribe Repository Corticotropin. *JAMA Network*
437 *Open*. 2018;1(2):e180482-e. <https://doi.org/10.1001/jamanetworkopen.2018.0482>.
- 438 [25] DeJong C, Aguilar T, Tseng C-W, Lin GA, Boscardin WJ, Dudley RA. Pharmaceutical
439 Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries. *JAMA*
440 *Internal Medicine*. 2016;176(8):1114-22. <https://doi.org/10.1001/jamainternmed.2016.2765>.
- 441 [26] Hartung DM, Johnston K, Van Leuven S, Deodhar A, Cohen DM, Bourdette DN.
442 Trends and Characteristics of US Medicare Spending on Repository Corticotropin. *JAMA*
443 *Internal Medicine*. 2017;177(11):1680-2. <https://doi.org/10.1001/jamainternmed.2017.3631>.
- 444 [27] Fickweiler F, Fickweiler W, Urbach E. Interactions between physicians and the
445 pharmaceutical industry generally and sales representatives specifically and their association with
446 physicians' attitudes and prescribing habits: a systematic review. *BMJ Open*. 2017;7(9):e016408.
447 <https://doi.org/10.1136/bmjopen-2017-016408>.
- 448 [28] Sharrak A, Nguyen T, Karabon P. Industry Research Payments to Urologists: The First
449 5 Years of Open Payments Research Data. *J Urol*. 2020;204(3):408-10.
450 <https://doi.org/10.1097/ju.0000000000001120>.
- 451 [29] Vanood A, Sharrak A, Karabon P, Fahim DK. Industry-Sponsored Research Payments
452 in Neurosurgery-Analysis of the Open Payments Database From 2014 to 2018. *Neurosurgery*.
453 2021;88(3):E250-e8. <https://doi.org/10.1093/neuros/nyaa506>.
- 454

455 Table 1. General payments to emergency physicians between 2013 and 2021

456

Variables	Program year									Overall
	2013 [†]	2014	2015	2016	2017	2018	2019	2020	2021	
General payments										
Total payments										
Payment amounts, \$	3,802,347	10,299,971	11,355,294	23,551,636	12,476,914	8,336,995	9,010,822	6,451,731	9,691,541	94,977,251
Number of payment contracts, n	17,023	41,903	48,400	48,813	43,546	36,957	35,858	20,325	28,603	321,428
Number of physicians with payment, n (%)	6,627 (13.1)	10,433 (20.7)	13,126 (26.0)	12,418 (24.6)	11,628 (23.0)	10,343 (20.5)	9,935 (19.7)	6,486 (12.9)	7,672 (15.2)	28,590 (56.6)
Payments per physician, \$										
Median (IQR)	36 (15–111)	54 (19–131)	52 (18–125)	50 (19–125)	50 (19–125)	47 (18–129)	54 (19–135)	31 (16–103)	43 (18–125)	133 (45–356)
Average (SD)	574 (5,910)	987 (17,059)	865 (9,879)	1,897 (109,478)	1,073 (21,653)	806 (6,928)	907 (7,396)	995 (7,701)	1,263 (13,214)	3,322 (91,063)
Range	1–259,567	0.01–1,431,778	1–591,106	3–12,149,520	1–2,116,142	2–299,999	1–281,792	2–213,163	1–579,350	1–14,265,662
Gini index	0.990	0.989	0.984	0.993	0.988	0.986	0.987	0.993	0.993	0.975

457 Abbreviations: interquartile range (IQR), SD (standard deviation)

458 [†] The payment data in 2013 were payments made to physicians between August 1 and

459 December 30.

460

461 Table 2. General payments by categories

462

Payment categories	Payment amounts, \$ (%)	Number of payments, n (%)	Number of physicians accepting payments, n (%)
Non-CME speaking ^a	36,522,818 (38.5)	9,101 (2.8)	841 (1.7)
Consulting fees	33,292,171 (35.1)	11,901 (3.7)	1,348 (2.7)
Food and beverage	9,264,816 (9.8)	274,678 (85.5)	27,966 (55.4)
Travel and lodging	6,314,702 (6.6)	16,945 (5.3)	1,543 (3.1)
Honoraria	3,102,053 (3.3)	1,672 (0.5)	613 (1.2)
CME speaking fees ^b	1,521,937 (1.6)	703 (0.2)	109 (0.2)
Royalty or license	1,387,444 (1.5)	92 (0.03)	13 (0.03)
Current or prospective ownership or investment interest	1,249,771 (1.3)	45 (0.01)	18 (0.04)
Education	617,592 (0.7)	5,379 (1.7)	2,964 (5.9)
Grant	525,701 (0.6)	43 (0.01)	33 (0.1)
Long term medical supply or device loan	436,062 (0.5)	21 (0.01)	13 (0.03)
Acquisitions	383,421 (0.4)	4 (0.001)	3 (0.03)
Gift	341,173 (0.4)	679 (0.2)	415 (0.8)
Entertainment	8,889 (0.01)	159 (0.05)	104 (0.2)
Charitable contribution	8,700 (0.01)	6 (0.002)	5 (0.01)

463 ^aNon-CME speaking payments included “compensation for services other than
464 consulting, including serving as faculty or as a speaker at a venue other than a
465 continuing education program.”

466 ^bCME speaking payments included “compensation for serving as faculty or as a speaker
467 for an accredited or certified continuing education program” (applicable to program
468 years 2013-2020), “compensation for serving as faculty or as a speaker for an
469 unaccredited and non-certified continuing education program” (applicable to program
470 years 2013-2020), and “compensation for serving as faculty or as a speaker for medical
471 education program” (applicable beginning with program year 2021 and subsequent
472 program years).

473 Table 3. Research payments to emergency physicians between 2013 and 2021

474

Variables	Program year									Overall
	2013 [†]	2014	2015	2016	2017	2018	2019	2020	2021	
Total payments										
Payment amounts, \$	11,063,957	46,283,114	50,728,394	53,123,761	45,116,819	29,602,868	32,481,344	37,374,351	56,888,938	362,663,547
Number of payment contracts, n	1,282	8,555	8,904	4,123	3,146	2,653	2,927	2,509	65,440	99,539
Number of physicians with specific payment amount, n (%)	114 (0.2)	235 (0.5)	279 (0.6)	304 (0.6)	283 (0.6)	230 (0.5)	218 (0.4)	207 (0.4)	188 (0.4)	663 (1.3)
Payments per physician, \$										
Median (IQR)	15,386 (4,834–101,900)	19,541 (3,676–95,671)	25,798 (7,000–95,870)	25,752 (8,730–75,740)	22,364 (5,080–88,625)	25,782 (6,502–118,337)	33,503 (8,081–122,299)	41,725 (12,320–127,927)	44,943 (11,453–200,961)	62,843 (10,320–273,285)
Average (SD)	97,052 (358,714)	196,949 (667,820)	181,822 (571,058)	174,749 (790,249)	159,423 (516,423)	128,708 (357,725)	148,997 (373,344)	180,552 (449,742)	302,601 (747,921)	547,004 (1,884,010)
Range	155– 3,762,707	0.1– 7,620,044	5–5,044,803	34–7,967,500	20–5,584,456	1–3,693,1101	12–4,111,636	105– 3,448,920	12–5,391,808	0.1– 22,538,680
Gini index	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.999	0.998

475 *p<0.05, **p<0.01, ***p<0.001

476 Abbreviations: interquartile range (IQR), SD (standard deviation)

477 [†] The payment data in 2013 were payments made to physicians between August 1 and
478 December 30.

479

480

481 Table 4. Trends in general and research payments between 2014 and 2021

482

	Relative annual average change rate (95% confidence interval), %		
	From 2014 to 2019	2014-2019 vs 2020-2021	From 2020 to 2021
General payments			
Number of physicians receiving payments	-2.9 (-3.2 – -2.5)***	-47.8 (-49.8 – -45.6)***	21.7 (19.8 – 24.8)***
Payments per physician	0.3 (-3.9 – 4.6)	-45.4 (-57.7 – -29.6)***	25.7 (5.9 – 49.2)**
Research payments			
Number of physicians receiving payments	-2.8 (-5.3 – -0.1)*	-5.2 (-20.3 – 12.8)	-6.6 (-17.0 – 5.1)
Payments per physician	-8.8 (-17.8 – 1.2)	-27.6 (-56.4 – 21.4)	69.4 (28.9 – 122.7)***

483 *p<0.05, **p<0.01, ***p<0.001

484 Payments for acquisitions, debt forgiveness, current or prospective ownership or
 485 investment interest, and royalty or license were excluded from the trend analysis of
 486 general payments.

487

488